CVI Holdings’s Cyclerion Therapeutics CYCN Stock Holding History

CVI Holdings’s Portfolio CYCN Stock Details CYCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-3,928	Closed	-$899K	–	45
2019 Q2	$899K	Buy	+3,928	New	+$1.11M	1.04%	18

Other funds holding CYCN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

CVI Holdings's CYCN Position: Q3 2019 in Review

CVI Holdings sold out of Cyclerion Therapeutics (CYCN) in Q3 2019, closing a stake of 3,928 shares — an estimated $899K sold.

CVI Holdings first reported a position in CYCN in Q2 2019 and held it in 1 quarter. The position peaked at $899K in Q2 2019. 90 funds tracked by Wall St. Rank hold CYCN as of Q3 2019.

CVI Holdings reported no remaining Cyclerion Therapeutics position as of Q3 2019 after selling out during the quarter.
CVI Holdings sold 3,928 Cyclerion Therapeutics shares in Q3 2019, an estimated $899K.
CVI Holdings first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 1 quarter.
CVI Holdings's Cyclerion Therapeutics position peaked at $899K in Q2 2019.
90 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q3 2019.

Based on CVI Holdings's 13F filing for Q3 2019, filed 14 Nov 2019.